S. 1097

119th Congress

Reported

Interagency Patent Coordination and Improvement Act of 2025

Sponsored byDemocrat:Sen. Durbin, Richard J. [D-IL]IL· Introduced 24 mars 2025

4

Cosponsors

6

Actions

0

Amendments

0

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

10 avril 2025·1 year ago

Summary

Introduced in Senate · Updated 17 juin 2025

Interagency Patent Coordination and Improvement Act of 2025

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.

Timeline

6 actions

  1. Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

    10 avril 2025 · Calendars

  2. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 avril 2025 · Committee

  3. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 avril 2025 · Committee

  4. Committee on the Judiciary. Ordered to be reported with amendments favorably.

    3 avril 2025 · Committee

  5. Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)

    24 mars 2025 · IntroReferral

  6. Introduced in Senate

    24 mars 2025 · IntroReferral

Sponsorship

4 cosponsors

Cosponsors

  • Democrat250%
  • Republican250%

Classification

Policy area

Commerce

Legislative subjects

Drug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Intellectual propertyIntergovernmental relations
Pelosi Tracker
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.